Blinatumomab for MRD-Positive B-Cell Precursor ALL: An 18-Month Follow-up

December 5-8, 2015; Orlando, Florida
Patients with complete MRD response after blinatumomab treatment had prolonged OS, RFS, and DoR vs those with an incomplete MRD response.
Format: Microsoft PowerPoint (.ppt)
File Size: 381 KB
Released: December 14, 2015


Educational grant provided by:
Celgene Corporation
Merck & Co., Inc.
Seattle Genetics
Takeda Oncology

Related Content

Downloadable resource guide for patients who are receiving an FDA-approved BTK inhibitor, acalabrutinib or ibrutinib, from CCO.

Released: June 20, 2019

Downloadable slides on treatment strategies for CLL including the most recent data on BTK inhibitors, BCL-2 inhibitor, PI3K inhibitors, and CAR T-cell therapy.

John M. Burke, MD Nicole Lamanna, MD Released: June 19, 2019

Enter characteristics of your patient with acute myeloid leukemia (AML) into this online tool to receive treatment recommendations from 5 experts

Jeffrey E. Lancet, MD Farhad Ravandi, MD B Douglas Smith B. Douglas Smith, MD Roland B. Walter, MD, PhD, MS Eunice S. Wang, MD Released: June 12, 2019

Results from a phase II trial of ibrutinib, lenalidomide, and rituximab in non-GCB DLBCL as reported by CCO from ASCO 2019

Released: June 11, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?